{"filings":[{"id":835556,"accession_number":"0001757073-26-000051","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-06-03T20:54:52+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envista CAO Faez Kaabi to retire Aug 6, 2026; Coree Thomas appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Faez Kaabi notified resignation as CAO and principal accounting officer effective Aug 6, 2026, due to retirement.","No disagreement with the company over financial disclosures or accounting matters cited for departure.","Kaabi will remain in role through transition; Coree Thomas appointed VP and CAO effective Aug 6, 2026.","Thomas, 48, has served as VP Global Controller since Feb 2023; prior roles at CBRE, Edwards Lifesciences, Exelon, KPMG.","No family relationships or related party transactions disclosed with Thomas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582516,"accession_number":"0001757073-26-000043","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-05-21T20:24:18+00:00","items":["5.07","9.01"],"status":"ready","headline":"Envista Holdings 2026 annual meeting: all 8 directors elected; EY ratified; say-on-pay approved; annual vote adopted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all eight director nominees: votes for ranged from 145,760,570 to 149,459,395.","Ratified Ernst & Young as auditor for 2026: 152,689,635 for, 913,161 against, 65,730 abstain.","Approved say-on-pay with 144,475,242 votes for, 5,144,798 against, 73,034 abstain.","Advisory vote on frequency of future say-on-pay: 139,798,463 for one year, 9,840,878 for three years; company adopts annual vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95226,"accession_number":"0001757073-26-000040","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 2026: core sales +9.5%, adjusted EPS $0.36 (+50% YoY), new $300M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $706M, core sales growth 9.5% YoY; Specialty Products +8.4%, Equipment & Consumables +11.5%.","GAAP diluted EPS $0.23; adjusted diluted EPS $0.36 (+50% YoY).","Adjusted EBITDA $99M (+25% YoY), margin 14.0% (+120 bps).","Operating cash flow -$3M, free cash flow -$16M vs -$5M prior year.","Board authorized $300M share repurchase through Dec 2029; FY2026 guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":705500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108131,"accession_number":"0001757073-26-000005","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 2025: core revenue +10.8%, adj. EPS $0.38 (+58% YoY); FY 2026 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $751M; core sales +10.8% YoY; GAAP EPS $0.20; adjusted EPS $0.38 (+58%).","FY 2025 core sales +6.5%; adjusted EBITDA $372M (+26% YoY); adjusted EPS $1.19 (+63%).","FY 2026 guidance: core sales growth 2-4%, adj. EBITDA growth 7-13%, adj. EPS $1.35-$1.45.","Repurchased 9.2M shares for $166M in FY 2025; ~$84M repurchase capacity remaining.","All major businesses/geographies positive; Spark achieved positive operating margin in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2719500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124547,"accession_number":"0001757073-25-000055","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q3 core sales up 9.4%; adj EPS $0.32 vs $0.12 YoY; raises FY core sales growth outlook to ~4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $670M, core sales growth 9.4% YoY; all major businesses positive growth.","GAAP EPS ($0.18) on $30M tax charge; adjusted EPS $0.32 (+167% YoY); adjusted EBITDA $97M (+77%), margin 14.5%.","Spark aligners achieved positive operating margin; share repurchases of 2.1M shares for $41M in Q3.","Updated FY2025 guidance: core sales growth ~4% (prior 3-4%), adj EPS $1.10-$1.15 (prior $1.05-$1.15), adj EBITDA margin ~14%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":1968900000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124546,"accession_number":"0001757073-25-000053","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista releases 2024 Sustainability Report; $1.9M donated, safety incident rate down 13%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Donated $1.9M in goods/services via Envista Smile Project to expand oral care access for underserved communities.","Completed inaugural Scope 3 GHG emissions inventory to better manage environmental footprint.","Safety incident rate reduced by 13% year-over-year.","CEO Paul Keel highlighted progress across ESG focus areas including ethics, community, and environment.","Report available on company website; stakeholder feedback invited via sustainability@envistaco.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141232,"accession_number":"0001757073-25-000050","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Barbara B. Hulit resigns from Envista board effective Sept 26, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara B. Hulit submitted her resignation from the Board on September 15, 2025.","Resignation is effective September 26, 2025; she cited pursuit of another opportunity.","Her decision was not the result of any disagreement with the company on operations, policies, or practices.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141231,"accession_number":"0001757073-25-000042","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).","Core sales growth 5.6% YoY across all businesses and geographies, including Nobel Biocare in North America.","FY2025 guidance raised: core sales growth 3-4% (prior 1-3%), adjusted EPS $1.05-$1.15 (prior $0.95-$1.05).","Repurchased 4.8M shares for ~$82M in Q2; $150M remaining under buyback program.","YTD operating cash flow $89M, free cash flow $71M, down from $133M and $116M in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1299000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141230,"accession_number":"0001757073-25-000036","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envista appoints Stryker executive J. Andrew Pierce to Board, adds Audit Committee role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Andrew Pierce elected to Board effective July 14, 2025, expanding Board from 8 to 9 members.","Pierce is Group President, MedSurg & Neurotechnology at Stryker since 2019; 29-year Stryker veteran.","Pierce joins Audit Committee; Board committee composition updated accordingly.","He will receive standard non-employee director compensation, pro-rated for FY2025, plus equity awards and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159030,"accession_number":"0001628280-25-031044","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Envist stockholders approve all four proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with >99% support for most.","Ratification of Ernst & Young as auditor approved with 99.8% votes in favor.","Advisory vote on executive compensation approved with ~94% support.","Amendment to Omnibus Incentive Plan to add 6.425M shares approved with ~94% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159029,"accession_number":"0001757073-25-000026","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 sales $617M, adj. EPS $0.24, maintains 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $617M, core sales +0.2% YoY; net income $18M, adjusted net income $42M.","EPS $0.10, adjusted EPS $0.24 (ahead of expectations); adj. EBITDA $79M (12.8% margin).","Operating cash flow $0M, free cash flow ($5)M vs $29M last year; repurchased 1.1M shares for $19M.","Maintains FY2025 outlook: core sales growth 1-3%, adj. EPS $0.95-$1.05, adj. EBITDA margin ≈14%.","Growth in Consumables, Nobel Biocare, Spark; soft Diagnostics; China ortho down due to VBP preparations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":616900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177472,"accession_number":"0001757073-25-000006","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Envista authorizes $250M share repurchase program through Dec 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $250 million in common stock.","Program runs from Feb 5, 2025 to Dec 31, 2026.","Repurchases may be via open market, privately negotiated, accelerated or 10b5-1 plans.","No other material events reported in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177471,"accession_number":"0001757073-25-000005","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.","Full-year 2024 net loss $1.12B (incl. impairment), adjusted net income $127M vs $269M in 2023.","Free cash flow $124M in Q4, up 24% YoY; operating cash flow $132M, up 30%.","Implants improved with growth in Nobel Biocare, Implant Direct, Alpha-Bio; Spark aligners gained share and gross margin.","FY2025 guidance: core sales growth 1-3%, adjusted EBITDA margin ~14%, adjusted EPS $0.95-$1.05."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2510600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194201,"accession_number":"0001757073-24-000080","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista releases 2023 Sustainability Report with 26% reduction in Scope 1 GHG emissions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Absolute Scope 1 GHG emissions decreased 26% year-over-year; total (Scope 1+2) intensity down 3.5%.","Donated nearly $1.3 million to oral health non-profits through the Envista Smile Project.","Achieved 99% gender pay equity and 99% ethnic pay equity in the U.S.","Invested in Kaizen projects to improve sustainability and operational efficiency at multiple facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194200,"accession_number":"0001757073-24-000077","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q3: net income $8.2M ($0.05 EPS), core sales down 5.3%, adj EBITDA $54.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $8.2M ($0.05 diluted EPS) vs $21.5M ($0.12) in Q3 2023.","Adjusted net income $21.1M ($0.12 diluted EPS) vs $75.5M ($0.43) in Q3 2023.","Adjusted EBITDA $54.9M compared to $123.5M in prior-year quarter.","Core sales declined 5.3% YoY; reported sales $601.0M.","Full-year 2024 guidance reaffirmed: core sales -1% to -4%, adjusted EBITDA margin 10%-12%."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1857700000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210526,"accession_number":"0001757073-24-000065","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q2 net loss $1.15B on $1.15B goodwill impairment; guides FY core sales down 1-4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1,151.6M ($6.69 per share) includes $1,153.8M non-cash goodwill and intangible impairment.","Adjusted net income $18.5M ($0.11 adj EPS) vs $76.2M ($0.43) in Q2 2023.","Reported sales $633.1M; core sales declined 3.2% YoY; adjusted EBITDA fell to $63.0M from $126.2M.","FY 2024 guidance: core sales decline 1%-4%, adj EBITDA margin 10%-12%; expects Q3 further decline, Q4 return to growth.","CEO Paul Keel cited repositioning actions including new permanent CFO and Presidents for two largest businesses."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1256700000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210525,"accession_number":"0001757073-24-000063","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista appoints Eric Hammes as CFO, Stefan Nilsson and Veronica Acurio to lead Nobel Biocare and Ormco","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Hammes appointed CFO effective August 8, 2024; interim CFO Stephen Keller returns to lead investor relations.","Hammes compensation: base salary $575k, target bonus 75% of salary, LTI $1.2M, one-time cash $1.02M, RSUs $1.2M.","Stefan Nilsson named President of Nobel Biocare, effective July 15; previously CEO of Colosseum Dental Group.","Veronica Acurio named President of Orthodontics (Ormco), effective August 2; formerly President of 3M Medical Solutions Division.","CEO Paul Keel cites relevant dental and healthcare experience; appointments expand leadership team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228854,"accession_number":"0001757073-24-000059","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Envista's SVP & President of Orthodontics Eric Conley steps down effective June 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Conley notified Envista on May 27, 2024, that he will step down as SVP and President, Orthodontics.","Departure effective June 3, 2024; Conley is leaving to pursue another opportunity.","Decision not the result of any disagreement with Envista; no replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228853,"accession_number":"0001757073-24-000056","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Envista annual meeting results: officer exculpation approved, Paul Keel elected director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment to exculpate officers approved: 130.7M for, 27.6M against, effective May 21, 2024.","Paul Keel elected as additional director with 154.3M votes for (98.5% of votes cast).","All incumbent directors re-elected; Daniel Raskas received 91.8M for vs 66.6M withheld, lowest support.","Advisory say-on-pay approved: 148.8M for, 9.5M against.","Ratification of Ernst & Young as auditor passed with 160.9M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228852,"accession_number":"0001757073-24-000038","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q1 net income $23.6M, adjusted EPS $0.26 (down 32% YoY); Paul Keel appointed CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $623.6M, core sales up 0.4% YoY.","Net income $23.6M ($0.14 diluted EPS); adjusted net income $45.8M ($0.26 diluted EPS), down from $0.38 in Q1 2023.","Adjusted EBITDA $87.2M, down from $114.0M in Q1 2023.","Spark business grew double digits with expanding margins; value implant business returned to growth, consumables stabilized.","Paul Keel appointed CEO effective May 1, 2024; Amir Aghdaei remains Senior Advisor and shareholder."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":623600000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228851,"accession_number":"0001757073-24-000036","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista appoints Paul Keel as CEO effective May 1, 2024; succeeds Amir Aghdaei","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Keel, former CEO of Smiths Group plc, named President & CEO and board member effective May 1, 2024.","Base salary of $1.1M, target annual cash bonus of 150% of salary (max 300%), and initial equity awards valued at $6.5M for FY2024 plus $11M replacement equity.","Relocation reimbursement up to $650k (with gross-up), subject to clawback if employment terminated within 12 months for cause.","Outgoing CEO Amir Aghdaei to resign from board on same date and will serve as senior advisor during transition.","Employment agreement includes non-compete, non-solicitation, non-disparagement, and perpetual non-disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247496,"accession_number":"0001757073-24-000031","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Envista director Barbara Hulit terminates consulting agreement, effective Apr 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement with director Barbara Hulit signed Jan 2, 2024, for 180-day term.","Hulit gave termination notice on Mar 26; arrangement ends Apr 30, 2024.","Compensation: $124,800/month cash plus $1.5M in RSUs over six months.","No reason provided for early termination; Hulit continues as Envista director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247495,"accession_number":"0001757073-24-000022","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista announces planned CEO succession; Aghdaei to step down once successor appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Amir Aghdaei to step down upon appointment of successor; board formed search committee for external candidates.","Transition agreement signed Feb 22, 2024; Aghdaei eligible for target bonuses for FY2023 and FY2024 based on actual performance.","Aghdaei to receive FY2024 equity award of $5.5M and consulting fee of $1.5M over 18 months post-transition.","Aghdaei remains President/CEO until successor appointed; process expected to complete in 2024.","Under transition agreement, Aghdaei forfeits eligibility for severance under the existing severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247494,"accession_number":"0001757073-24-000011","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Envista Q4 net loss $217.4M on $258.3M impairment; adjusted EPS $0.29; guides FY2024 margin 16-17%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $645.6M, core sales down 2.0% YoY; net loss of $1.27 diluted EPS includes $258.3M goodwill/intangibles impairment.","Adjusted net income $49.7M ($0.29 EPS) vs $91.9M ($0.52 EPS) in Q4 2022; adjusted EBITDA $100.5M vs $138.3M.","FY2023 free cash flow $223.6M, up >$100M vs 2022; orthodontic Spark Aligner grew over 50% for the year.","FY2024 guidance: core sales low-single-digit growth; adjusted EBITDA margin of 16%-17%, down from 18.1% in FY2023.","CEO cites volatile macro, plans to improve Spark profitability and accelerate North American implant business in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":2566500000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264957,"accession_number":"0001757073-23-000078","cik":1757073,"company_name":"Envista Holdings Corp","ticker":"NVST","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Envista names three new executives; Nobel Biocare president exits Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrik Eriksson, SVP and President of Nobel Biocare, departs effective Dec 31, 2023.","Robert Befidi appointed President, Diagnostics; previously led division at 3M.","Suraj Satpathy appointed Chief Human Resources Officer; formerly SVP HR at Cepheid.","Andrew Chen appointed Chief Information Officer; previously CIO at Kite Pharma.","External search for permanent CFO is underway; CEO Aghdaei directly overseeing Nobel Biocare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3822478766.027027,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}